Figures
Abstract
Background
We have previously shown that ADP-induced TXA2 generation requires signaling from αIIbβ3 integrin in platelets. Here we observed that, unlike ADP, protease-activated receptor (PAR)-mediated TXA2 generation occurs independently of αIIbβ3. PAR agonists, but not ADP, activate G12/13 signaling pathways. Hence, we evaluated the role of these pathways in TXA2 generation.
Principal Findings
Inhibition of ADP-induced thromboxane generation by fibrinogen receptor antagonist SC57101 was rescued by co-stimulation of G12/13 pathways with YFLLRNP. This observation suggested an existence of a common signaling effector downstream of integrins and G12/13 pathways. Hence, we evaluated role of three potential tyrosine kinases; c-Src, Syk and FAK (Focal Adhesion Kinase) that are known to be activated by integrins. c-Src and Syk kinase did not play a role in ADP-induced functional responses in platelets. Selective activation of G12/13 pathways resulted in the activation of FAK, in the absence of integrin signaling. Interestingly, αIIbβ3-mediated FAK activation occurred in a Src family kinase (SFK)-independent manner whereas G12/13 pathway caused FAK activation in a SFK and RhoA-dependent manner. A FAK selective inhibitor TAE-226, blocked TXA2 generation. However, in comparison to WT mice, Pf4-Cre/Fak-Floxed mice did not show any difference in platelet TXA2 generation.
Citation: Bhavaraju K, Lakhani PR, Dorsam RT, Jin J, Hitchcock IS, Sanjay A, et al. (2011) G12/13 Signaling Pathways Substitute for Integrin αIIbβ3-Signaling for Thromboxane Generation in Platelets. PLoS ONE 6(2): e16586. https://doi.org/10.1371/journal.pone.0016586
Editor: Christian Schulz, German Heart Center, Germany
Received: September 8, 2010; Accepted: December 21, 2010; Published: February 10, 2011
Copyright: © 2011 Bhavaraju et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work is supported by HL81322, HL80444 and HL60683 from National Institutes of Health to SPK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Platelet activation is an essential component of hemostasis and thrombosis, and involves engagement of complex signaling machinery. Injury to sub-endothelium results in platelet adhesion, and subsequent spreading on exposed collagen. Platelet activation also leads to reorganization of platelet cytoskeleton, release of granular contents from dense and alpha granules and finally culminates in integrin activation leading to platelet aggregation [1], [2], [3]. ADP released from the dense granules and the thromboxaneA2 (TXA2) generated from activated platelets further act as positive feedback mediators and amplify the initial platelet responses and stabilize the hemostatic plug [4], [5].
TXA2 is generated from its precursor arachidonic acid through cycloxygenase pathway [6]. TXA2 acts on the TP (Prostanoid) receptors and recruits more platelets to the site of injury. Platelets can be activated by broad range of agonists, which can be further classified as strong or weak. ADP, serotonin, and epinephrine, are considered weak agonists [7] whereas thrombin, SFLLRNP (PAR1 agonist), AYPGKF (PAR4 agonist) [8], and Convulxin (GP VI agonist) [9] are strong agonists. Not only these agonists activate platelets with varied potencies but they also induce distinct signaling pathways. Previous studies have shown that ADP-induced TXA2 generation in platelets is integrin-dependent [10] however; it is not known whether stronger agonists such as thrombin depend on integrin-mediated signaling for TXA2 generation.
ADP activates two G-protein coupled receptors P2Y1 and P2Y12, activating Gq and Gi pathways, respectively [1], [3]. In platelets, neither of the ADP receptors can couple to G12/13 proteins whereas PAR receptors couple to G12/13 proteins [11]. G12/13 pathways have been shown to activate Rho kinase [12] and Src family kinases (SFKs) [13]. Earlier studies have shown that G12/13 pathways mediate calcium-independent shape change [12], [14], and play a potentiating role in Akt phosphorylation [13] and dense granule secretion [15]. Co-stimulation of platelets with G12/13 and Gi also leads to platelet aggregation [16].
Agonist binding to platelet receptors results in complex intracellular signaling events termed as inside-out signaling, which leads to the activation of integrins αIIbβ3 and α2β1. Activated integrins change conformation and bind multivalent ligands such as fibrinogen and von Wilebrand Factor (vWF) [17]. Signaling events from ligand binding to fibrinogen receptor are termed as outside-in signaling which, in turn regulate platelet adhesion, spreading, and clot retraction [18]. Outside-in signaling also causes phosphorylation of β3 cytoplasmic tails [19], [20], and activation of Phospholipase C (PLC γ) [21], tyrosine kinases such as c-Src, Syk [21] and Focal adhesion kinase (FAK) [22]. FAK is a 125 kDa protein, expressed in both megakaryocytes and platelets [23]. FAK is tyrosine phosphorylated on six tyrosine residues viz., Y397, Y407, Y576/577, Y861 and Y925 [24].
Other signaling molecules, involved in outside-in signaling are Protein Tyrosine Phosphatase-1B (PTP-1B) [25], Protein Phosphatase 1C (PP1c) [26], Calcium and integrin binding protein (CIB) [27] and Protein Kinase C-β (PKC-β) [28], [29].
In this study we show that, G12/13 pathways, cause TXA2 generation even when signaling from integrin is blocked. We present an evidence that c-Src and Syk kinase do not play a role in ADP-induced functional responses and FAK can be activated downstream of integrin αIIbβ3 as well as G12/13 pathways. However, G12/13-mediated activation of FAK occurs via Rho kinase and SFKs, whereas integrin-mediated FAK activation is independent of SFKs. Studies to evaluate the role of FAK in thromboxane generation showed that FAK does not contribute to thromboxane generation downstream of integrins. In conclusion, neither c-Src, Syk nor FAK contribute to integrin-mediated thromboxane generation in platelets. Therefore, the common signaling molecule downstream of integrins and G12/13 remains yet to be identified.
Results
Regulation of thromboxane generation in platelets by G12/13 pathways
ADP-induced TXA2 generation is dependent on integrin activation and as pre-treatment of platelets with fibrinogen receptor antagonist (SC57101) abrogated ADP-induced TXA2 generation [10]. We investigated the effect of a fibrinogen receptor antagonist (SC57101) on PAR-mediated TXA2 generation. Searle Research developed SC57101 (Skokie, IL) based on the RGDS structure. SC57101 and its analogs are fibrinogen receptor antagonists and do not affect inside out signaling [10]. As shown in Fig. 1A, varying concentrations of AYPGKF, a PAR4 agonist, caused TXA2 generation in the presence or absence of SC57101, indicating that PAR agonists cause thromboxane generation independently of integrin signaling. One of the main signaling differences between ADP and PAR agonists is that only PAR agonists can activate G12/13 pathways [11]. In order to evaluate the role of G12/13 pathways in platelet TXA2 generation we co-stimulated platelets with 2MeSADP and/or YFLLRNP. 2MeSADP is a more potent agonist than ADP at the P2Y1 and P2Y12 receptors [30] and YFLLRNP is a weak agonist of PAR1 that selectively activates G12/13 pathways (at low doses) [16], [31]. As shown in Fig. 1B, 2MeSADP-induced thromboxane generation was completely blocked in the presence of SC57101. YFLLRNP alone did not cause any significant TXA2 generation in human platelets. However, co-stimulation of platelets with 2MeSADP and YFLLRNP in presence of SC57101 caused TXA2 generation, indicating that the G12/13 pathways can rescue the inhibition rendered by fibrinogen receptor antagonist. Hence, G12/13 pathways can substitute for integrin-mediated signaling by probably activating similar effector molecules.
Non-aspirin-treated, washed human platelets were stimulated with different concentrations of AYPGKF in presence and absence of SC57101 (10 µM) (A) or other agonists (B) as indicated for 3.5 minutes at 37°C under stirring conditions (900 rpm) in an aggregometer. After 3.5 minutes the reaction was stopped by snap- freezing in dry ice-methanol bath. TXB2 levels were analyzed as described in “Materials and Methods”. The values are representative of 3 independent experiments mean ± S.E.M (n = 3). The data were analyzed by student t-test and ANOVA, ** P≤0.005 was considered significant.
Role of c-Src and Syk downstream of integrin αIIbβ3 in thromboxane generation in platelets
Previous studies have shown that c-Src and Syk are signaling effectors in platelets that are regulated by integrins [32]. In order to identify the common signaling molecules downstream of fibrinogen receptor and G12/13 pathways, we evaluated the role of these individual kinases in ADP-induced TXA2 generation. We reasoned that as these tyrosine kinases are activated downstream of fibrinogen receptor and because ADP-induced thromboxane generation requires signaling events from fibrinogen receptor, at least one of these kinases could be crucial for ADP-induced thromboxane generation. 2MeSADP-induced phosphorylation of c-Src Y416 occurred in a time and concentration-dependent manner (Figs. 2A and B). However, 2MeSADP-induced TXA2 generation in wild type mice was not different from the c-Src knockout mice (Fig. 2C), suggesting that either other Src family members may compensate for the absence of c-Src or that c-Src activation downstream of ADP receptors is not involved in TXA2 generation. We then studied Syk kinase activation downstream of ADP receptors. Syk kinase was not activated downstream of ADP receptors (Fig. 2D), as determined by the phosphorylation of the Tyr525/526 residues [33]. Taken together, these results suggest, that c-Src and Syk may not be not essential for ADP-induced thromboxane generation in platelets.
Aspirin–treated, washed platelets were stimulated with 2MeSADP (100 nM) at various time points (A) or with varying concentrations of 2MeSADP (B) for one minute under stirring conditions at 37°C. The lysates were then subjected to western blotting analysis and probed with anti-phospho-(Y416) and total c-Src antibodies as lane loading control. Washed murine (WT or c-Src KO) platelets, without aspirin-treatment, were stimulated with 2MeSADP (100 nM) for 3.5 minutes and TXB2 levels were analyzed (C) as described for Figure 1. The data are represented as the % Fold increase over the control. Aspirin-treated washed platelets were stimulated with 2MeSADP (100 nM) for (30–120 seconds) or convulxin (100 ng/ml) for 30 seconds under stirring conditions at 37°C (D). The lysates were then subjected to western blotting analysis and probed with anti- phospho- Syk(Y 525/526) and total Syk antibodies as lane loading control. The data are representative of at least 3 separate experiments.
Focal Adhesion Kinase is activated downstream of integrins and G12/13 pathways
We next evaluated the activation of FAK by ADP receptors, using Y397 phosphorylation as an activation marker. FAK contains multiple tyrosine phosphorylation sites and the sequential tyrosine phosphorylations of these sites causes complete FAK activation beginning with autophosphorylation Y397 phosphorylation [34]. As shown in Figs. 3A & B, FAK is activated downstream of ADP receptors and this activation is blocked by a fibrinogen receptor antagonist but not by a pan SFK inhibitor PP2. These results indicate FAK activation by ADP occurs in an integrin-clustering-dependent manner, independent of SFKs.
Aspirin treated, washed platelets were stimulated with 2MeSADP (100 nM) in presence or absence of reagents (as indicated) for 60 seconds under stirring conditions at 37°C (A). The lysates were then subjected to western blotting analysis and probed with anti- phospho- FAK (Y-397) and total FAK antibodies as lane loading control. The data are representative of mean ± S.E.M (n = 3). The data was analyzed by ANOVA and * P≤0.05 was considered significant (B). Aspirin-treated washed platelets were stimulated with AYPGKF (500 µM) in presence or absence of YM254890 (150 nM) (C), The lysates were then subjected to western blotting analysis and probed with anti- phospho- FAK (Y-397) and total FAK antibodies as lane loading control.
We further investigated FAK activation downstream of G12/13 pathways. PAR agonists activate both Gq and G12/13 pathways in platelets [11]. The Gq pathways can be inhibited by YM254890 [35] without affecting the Gi or G12/13 pathways [13]. Since YFLLRNP is a weak, agonist for G12/13 pathways at low concentrations and at higher concentrations can also activate Gq pathways [16], we chose to stimulate platelets with AYPGKF (500 µM) in the presence of YM254890 as tool for selective and strong activation of G12/13 pathways for our phosphorylation studies [13]. As shown in Fig. 3C, AYPGKF caused activation of FAK in human platelets as determined by the phosphorylation of Y397 residue. This phosphorylation was unaffected in the presence of YM254890. It is important to note that 150 nM of YM254890 abrogates AYPGKF-induced platelet aggregation and secretion [13] and hence autophosphorylation of FAK on Y397 is through G12/13 pathways but not by outside-in signaling.
Signaling pathways regulating FAK activation downstream of G12/13 pathways
We have shown that G12/13 pathways activated by AYPGKF in the presence of YM254890 can activate FAK (Fig. 3A). Under these conditions we used pharmacological inhibitors to evaluate the signaling molecules that could regulate FAK phosphorylation. As shown in Figs. 4A&B, PP2, a pan SFK inhibitor abolished FAK phosphorylation mediated by G12/13 pathways. Our results from Figs. 4C&D show that Rho kinase inhibitors H1152 and Y27632 also markedly inhibited G12/13-mediated FAK phosphorylation. These results indicate that both SFKs and Rho kinase play an important role in FAK activation downstream of G12/13 pathways in platelets. In order to further delineate the signaling pathways downstream of G12/13, we also studied Src Y416 phosphorylation in presence of Rho kinase inhibitors. As shown in Figs. 4E&F, G12/13-mediated Src Y416 phosphorylation was dramatically inhibited in presence of Rho kinase inhibitors H1152 and Y27632, thus suggesting that SFKs are activated downstream of Rho kinase in the G12/13 signaling cascade.
Aspirin-treated, washed human platelets were pre-treated with different inhibitors (as indicated) for 5 minutes at 37°C followed by stimulation with AYPGKF (500 µM) for 90 seconds under stirring conditions at 37°C in an aggregometer. The lysates were then subjected to western blotting analysis and probed with anti- phospho FAK (Y-397) and total FAK antibodies as lane loading control (A &C) or anti- phospho- Src (416) and total c-Src antibodies as lane loading control (E). Quantitative data, normalized to the lane loading control, are representative of mean ± S.E.M (n = 3). The data was analyzed by ANOVA and * P≤0.05 was considered significant (B, D, and F).
Evaluation of FAK as a common signaling effector molecule regulating thromboxane generation downstream of integrins and G12/13 pathways
We next evaluated whether activated FAK played a role in ADP-induced TXA2 generation. TAE-226 has recently been identified as a selective inhibitor of FAK with an IC50 of 5.5 nM [36]. To determine the effect of FAK inhibition on ADP-induced thromboxane generation platelets were treated with varying concentrations of TAE-226. As demonstrated in Fig. 5A, TXA2 generation was significantly inhibited by TAE-226 at a higher concentration of 2 µM. Pharmacological inhibitors are often known to have off target and broad-spectrum effects. The specificity of TAE-226 was never evaluated in platelets and reports suggest that TAE-226 inhibits Pyk2 (a Focal Adhesion kinase family member) with an IC50 of 5 nM [37]. Hence, we studied thromboxane generation in WT and Pf4-Cre/FAK-floxed mice platelets. Murine platelets from WT and Pf4-Cre/FAK-floxed were stimulated with 100 nM of 2MeSADP and thromboxane levels were measured from WT and Pf4-Cre/FAK-floxed mice samples. As shown in Fig. 5B there was no significant difference observed thromboxane levels and aggregation tracings (Fig. 5C) between WT and Pf4-Cre/FAK-floxed. These results suggest that TAE-226 might exhibit some non-specific effects, and FAK is not the common signaling molecule regulating thromboxane generation downstream of integrins and G12/13 pathways.
Non-aspirin-treated, washed human platelets were pre-treated with varying concentrations of TAE-226 for 5 minutes at 37°C (A) and murine platelets from WT and Pf4-Cre/Fak-Floxed mice (B) were stimulated with 2MeSADP (100 nM) for 3.5 minutes and TXB2 levels were analyzed as described for Figure 1. Aggregation tracings were measured from WT and Pf4-Cre/Fak-Floxed mice and representative tracings are shown (C). The values are representative of 3 independent experiments mean ± S.E.M (n = 3). The data were analyzed by ANOVA and student t-test, * P≤0.05 was considered significant.
Discussion
Activated platelets release positive feedback mediators such as ADP and TXA2. The molecular mechanisms involved in thromboxane generation by different platelet agonists are not clearly understood. Weaker agonists such as ADP require outside-in signaling through activated fibrinogen receptor to cause thromboxane generation in platelets. Patients with Glanzmann's thrombasthenia show defective thromboxane generation with ADP but not with thrombin [38]. Our results show that PAR agonists mediate TXA2 generation independent of the integrin signaling. Previous studies by Stefanini et al [39] showed that stimulation of platelets with high and low doses of GPVI agonist convulxin in the presence of integrin blockers showed a marginal decrease in thromboxane generation, indicating that thromboxane generation downstream of GPVI receptors is not solely dependent on integrins. Thus, these results indicate that platelets can generate thromboxane in an integrin-dependent and-independent manner. Since PAR receptors can activate G12/13 pathways we reasoned that there might be a common signaling molecule, which could be activated by both G12/13 pathways (which are not activated by ADP) and integrins. This common signaling molecule might regulate TXA2 generation downstream of G12/13 pathways independent of integrins.
It has been known that several platelet agonists cause activation of G12/13, but not much is known about the intracellular signaling pathways downstream of this activation. Studies from our group have shown that G12/13 pathways activate Src family kinases in platelets [13]. Klages et al [12] showed that G12/13 proteins can activate tyrosine kinases such as Syk and c-Src. Interestingly these kinases are also known to be activated downstream of outside-in signaling [32]. Although integrins and G12/13 pathways activate c-Src, it is clear that this kinase has no significant role in thromboxane generation downstream of ADP receptors (Fig. 2C). Interestingly, thromboxane A2, an agonist that couples to Gq and G12/13 [11], still caused the phosphorylation of p72Syk in Gq-deficient mice [12]. This result suggests that activation of Syk might occur downstream of G12/13 signaling. However, Syk does not appear to be activated downstream of ADP receptors (Fig. 2D). Hence, both c-Src and Syk can be ruled out as the common signaling molecule mediating thromboxane generation downstream of G12/13 and integrin pathways.
Our studies show that FAK is differentially activated downstream integrins (Figs. 3A and B) and G12/13 pathways (Figs. 3C, 4A and B). However, recently it was reported by Gong et al [40] that G13 binds to integrin αIIbβ3 and mediates outside-in signaling. Gong et al claim that Rho activation downstream of PARs and integrins is temporally and spatially regulated and mediates opposing effects. With regards to FAK activation in platelets it does not seem to be the probable mechanism since ADP-induced FAK activation is independent of SFKs (Figs. 3A and B) and downstream of G12/13 pathways FAK activation is SFK and Rho-dependent (Figs. 4A and 4C). Thus, there maybe some other integrin-mediated signaling pathways regulating FAK activation in platelets. Upstream of FAK, SFKs are activated by G12/13 pathways [13]. SFKs regulate FAK activation downstream of G12/13 pathways but not downstream of integrin signaling (Figs. 4A and 3A). Although integrin signaling leads to c-Src and FAK activation, our results suggest that Src/Syk pathways and FAK pathways are independently activated by integrins as outlined in Fig. 6, with possible differential functional implications in platelets.
Integrin clustering leads to FAK activation (1). Fibrinogen receptor antagonist SC57101 prevents integrin clustering hence inhibits FAK activation (2). FAK can be activated in an integrin-independent manner by G12/13 pathways (3). FAK is activated downstream of Rho kinase and SFKs upon stimulation of G12/13 pathways (4). FAK can be inhibited by TAE-226 (5). Common effector molecule downstream of integrins and G12/13 pathways contributing to thromboxane generation are unknown (6).
G12/13 pathways are known to activate RhoA/Rho kinase pathways leading to calcium-independent shape change [12], [14]. These pathways are also known to regulate dense granule release through RhoA/Rho kinase pathways [15]. Our studies show that Rho kinase pathways regulate FAK activation through SFKs (Figs. 4E&F). This is a novel observation and indicates that Rho kinase pathways are the nodal point of SFK activation, ppIMδ phosphatase, and other pathways regulating dense granule release. We postulate that these pathways are independent of each other as; inhibition of SFKs (with PP2) has no significant effect on PAR-mediated shape change or dense granule release in aspirin-treated platelets [41]. Hence, SFK activation occurs downstream, rather than upstream, of RhoA/Rho kinase pathways upon G12/13 stimulation as outlined in Fig. 6. If SFK activation were to occur upstream of Rho kinase pathways, then SFK inhibition would have affected platelet shape change as well as dense granule release reaction in aspirin-treated platelets.
Furthermore, complementary approaches e.g. pharmacological FAK inhibitor TAE-226 and Pf4-Cre/Fak-Floxed mice were employed to evaluate role of FAK in thromboxane generation. Pre-treatment of platelets with various doses of TAE-226 did not lead to significant decrease in thromboxane levels. However, inhibition of thromboxane generation was observed at 2 µM concentration only (Fig. 5A). Similarly thromboxane generation was not affected in Pf4-Cre/Fak-Floxed mice, when compared to WT littermates (Fig. 5B). These results indicate that FAK does not contribute to thromboxane generation downstream of integrins and TAE-226 might have some non-specific effects on platelets.
Since our data indicates that loss of FAK does not translate into diminished thromboxane generation, it is possible that some other tyrosine kinases might be compensating for the loss of FAK in platelets, however it might be unlikely since previous studies in Pf4-Cre/Fak-Floxed mice showed differences in tail bleeding times and platelet spreading and no upregulation of Pyk2 expression was observed in FAK-Floxed mice [23]. Recently, another FAK inhibitor PF-573,228 was shown to inhibit platelet aggregation [42]. However, our platelet aggregation studies comparing WT and Pf4-Cre/FAK-Floxed mice did not show any differences in aggregation (Fig. 5C). Furthermore, as our previous studies have shown that ERK can be activated even in the presence of integrin antagonists [43] therefore, ERK cannot be the common effector downstream of integrins and G12/13 pathways.
Thus, we conclude that G12/13 pathways through a Rho kinase/SFK dependent manner activate FAK. However, FAK activation downstream of integrins occurs independently of SFKs. Finally none of the three-tyrosine kinases c-Src, Syk or FAK seems to play a role in thromboxane generation downstream of integrins. Thus, the common signaling effector, possibly a tyrosine kinase, contributing to thromboxane downstream of G12/13 pathways and integrins remains yet to be identified.
Materials and Methods
Materials
2MeSADP, Apyrase grade VII, human fibrinogen, acetylsalicylic acid, were obtained from Sigma (St. Louis, MO). SC57101 was gift from Searle Research and Development (Skokie, IL). Hexapeptide AYPGKF was custom synthesized at Invitrogen (Carlsbad, CA). Convulxin was purchased from Centerchem Inc. (Norwalk, CT). The heptapeptide, YFLLRNP was synthesized by New England Biolabs (Beverly, MA) or by Research Genetics (Huntsville, AL). Phospho-specific antibodies against Y416 Src family, anti-Syk Y525/526, Total Src and Total Syk were obtained from Cell Signaling Technologies (Beverly, MA). Antibodies against FAK Y397 were obtained from Millipore, (Bedford, MA) and Total FAK was from Biosource (Camarillo, USA). PP2 and PP3 were purchased from Biomol (Plymouth Meeting, PA). The Rho kinase inhibitor H1152 was obtained from Toronto Research Chemicals (North York, ON). Y-27632 was obtained from Calbiochem (San Diego, CA). YM-254890 was a gift from Yamanouchi Pharmaceuticals Co., Ltd (Ibaraki, Japan). TAE-226 was generously provided by (Novartis Pharma AG, Switzerland). The other reagents were of reagent grade, and de-ionized water was used throughout.
Animals
8–12 weeks old Pf4-Cre, and Pf4-Cre/FAK-floxed mice were generated in accordance with previously described protocol [44]. The generation of Src KO mice was described previously [45] and these mice along with wild type littermates in C57BL/6 background were used in the experiments.
Preparation of washed human and murine platelets
All experiments with human volunteers were performed in accordance with Declaration of Helsinki. Whole blood was drawn from healthy, human volunteers selected from students, staff or workers at the Temple University with written informed consent. Donated blood was collected in tubes containing one-sixth volume of acid citrate dextrose (ACD) (2.5 g of sodium citrate, 1.5 g of citric acid, and 2 g of glucose in 100 ml of de-ionized water). Citrated blood was centrifuged and platelets were isolated with previously established protocol [46].
Isolation of mouse platelets
Blood was collected from the vena cava of anaesthetized mice into syringes containing one-tenth blood volume of 3.8% sodium citrate as anticoagulant. Red blood cells were removed by centrifugation at 100× g for 10 min. PRP was recovered, and platelets were pelleted at 400× g for 10 min. The platelet pellet was resuspended in Tyrode's buffer (pH 7.4) containing 0.01 unit/ml apyrase. The isolated platelets were subsequently used for experiments.
Western blot analysis
Aliquots of aspirin-treated, washed human platelets were lysed using Laemmli buffer in presence of dithiothreitol (DTT) (100 mM) and boiled for 10 min. The platelet lysates were loaded onto a 10% -Tris-glycine gel, subjected to SDS-PAGE (Sodium Dodecyl Sulfate- Polyacrylamide Gel Electrophoresis), and transferred to PVDF membrane. Nonspecific binding sites were blocked by incubating the membrane in Tris–buffered saline-Tween (TBST; 20 mM Tris, 140 mM NaCl, 0.1% (vol/vol) Tween 20) containing 3% (wt/vol) bovine serum albumin (BSA) and 5% (vol/vol) Irish cream for 30 min at RT, followed by incubating it overnight at 4°C with gentle agitation in the primary antibody (1∶1000 dilution for anti-FAK Y397, anti-Src Y416, anti-Syk Y525/526, anti-Syk, Anti-FAK and anti-Src in TBST with 3% BSA). After washing with TBST, the membranes were probed with an alkaline phosphatase-labeled secondary antibody (1∶5000 dilutions in TBST with 3% BSA) for 1 hour at RT. After additional washing steps, membranes were incubated with chlordiazepoxide (CDP)–Star® chemiluminescent substrate (Tropix, Bedford, MA) for 10 min at RT, and immunoreactivity was detected using a Fuji Film Luminescent Image Analyzer (LAS-3000 CH; Tokyo, Japan).
Measurement of TXA2 generation in human and mice platelets
Washed human platelets (500 µl brought to a concentration of 2×108 platelets/mL) were stimulated with 2MeSADP (100 nM) in a lumi-aggregometer at 37°C with stirring at 900 rpm, in the presence or absence of TAE-226. Similarly murine platelets from WT and Pf4-Cre/FAK-floxed mice (250 µl brought to a concentration of 2×108 platelets/mL) were stimulated with 2MeSADP (100 nM). After 3.5 min of stimulation, the reaction was stopped by quickly freezing the sample in a dry ice-methanol bath. The level of TXB2, the stable metabolite of TXA2 was measured using a previously established protocol [47].
Acknowledgments
We would like to thank Dr. Abdel Karim Sabri, Department of Anatomy and Cell Biology, and Dr. James L. Daniel, Department of Pharmacology, Temple University Medical School, for their helpful suggestions.
Author Contributions
Conceived and designed the experiments: KB ISH AS SPK. Performed the experiments: KB PRL RTD JJ. Analyzed the data: KB JJ SPK. Contributed reagents/materials/analysis tools: ISH AS. Wrote the paper: KB SPK.
References
- 1. Dorsam RT, Kunapuli SP (2004) Central role of the P2Y12 receptor in platelet activation. J Clin Invest 113: 340–345.
- 2. Freedman JE (2005) Molecular regulation of platelet-dependent thrombosis. Circulation 112: 2725–2734.
- 3. Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP (2006) Nucleotide receptor signaling in platelets. J Thromb Haemost 4: 2317–2326.
- 4. Ruggeri ZM (1997) Mechanisms initiating platelet thrombus formation. Thromb Haemost 78: 611–616.
- 5. Murugappan S, Shankar H, Kunapuli SP (2004) Platelet receptors for adenine nucleotides and thromboxane A2. Semin Thromb Hemost 30: 411–418.
- 6. Paul BZ, Jin J, Kunapuli SP (1999) Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem 274: 29108–29114.
- 7. Lages B, Weiss HJ (1988) Heterogeneous defects of platelet secretion and responses to weak agonists in patients with bleeding disorders. Br J Haematol 68: 53–62.
- 8. Brass LF, Hoxie JA, Kieber-Emmons T, Manning DR, Poncz M, et al. (1993) Agonist receptors and G proteins as mediators of platelet activation. Adv Exp Med Biol 344: 17–36.
- 9. Francischetti IM, Saliou B, Leduc M, Carlini CR, Hatmi M, et al. (1997) Convulxin, a potent platelet-aggregating protein from Crotalus durissus terrificus venom, specifically binds to platelets. Toxicon 35: 1217–1228.
- 10. Jin J, Quinton TM, Zhang J, Rittenhouse SE, Kunapuli SP (2002) Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors. Blood 99: 193–198.
- 11. Offermanns S, Laugwitz KL, Spicher K, Schultz G (1994) G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci U S A 91: 504–508.
- 12. Klages B, Brandt U, Simon MI, Schultz G, Offermanns S (1999) Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 144: 745–754.
- 13. Kim S, Jin J, Kunapuli SP (2006) Relative contribution of G-protein-coupled pathways to protease-activated receptor-mediated Akt phosphorylation in platelets. Blood 107: 947–954.
- 14. Paul BZ, Daniel JL, Kunapuli SP (1999) Platelet shape change is mediated by both calcium-dependent and -independent signaling pathways. Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change. J Biol Chem 274: 28293–28300.
- 15. Jin J, Mao Y, Thomas D, Kim S, Daniel JL, et al. (2009) RhoA downstream of G(q) and G(12/13) pathways regulates protease-activated receptor-mediated dense granule release in platelets. Biochem Pharmacol 77: 835–844.
- 16. Dorsam RT, Kim S, Jin J, Kunapuli SP (2002) Coordinated signaling through both G12/13 and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets. J Biol Chem 277: 47588–47595.
- 17. Shattil SJ, Newman PJ (2004) Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 104: 1606–1615.
- 18. Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, et al. (2009) Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood 113: 893–901.
- 19. Law DA, DeGuzman FR, Heiser P, Ministri-Madrid K, Killeen N, et al. (1999) Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature 401: 808–811.
- 20. Jenkins AL, Nannizzi-Alaimo L, Silver D, Sellers JR, Ginsberg MH, et al. (1998) Tyrosine phosphorylation of the beta3 cytoplasmic domain mediates integrin-cytoskeletal interactions. J Biol Chem 273: 13878–13885.
- 21. Wonerow P, Pearce AC, Vaux DJ, Watson SP (2003) A critical role for phospholipase Cgamma2 in alphaIIbbeta3-mediated platelet spreading. J Biol Chem 278: 37520–37529.
- 22. Hato T, Pampori N, Shattil SJ (1998) Complementary roles for receptor clustering and conformational change in the adhesive and signaling functions of integrin alphaIIb beta3. J Cell Biol 141: 1685–1695.
- 23. Hitchcock IS, Fox NE, Prevost N, Sear K, Shattil SJ, et al. (2008) Roles of focal adhesion kinase (FAK) in megakaryopoiesis and platelet function: studies using a megakaryocyte lineage specific FAK knockout. Blood 111: 596–604.
- 24. Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6: 56–68.
- 25. Arias-Salgado EG, Haj F, Dubois C, Moran B, Kasirer-Friede A, et al. (2005) PTP-1B is an essential positive regulator of platelet integrin signaling. J Cell Biol 170: 837–845.
- 26. Vijayan KV, Liu Y, Li TT, Bray PF (2004) Protein phosphatase 1 associates with the integrin alphaIIb subunit and regulates signaling. J Biol Chem 279: 33039–33042.
- 27. Naik UP, Patel PM, Parise LV (1997) Identification of a novel calcium-binding protein that interacts with the integrin alphaIIb cytoplasmic domain. J Biol Chem 272: 4651–4654.
- 28. Buensuceso CS, Obergfell A, Soriani A, Eto K, Kiosses WB, et al. (2005) Regulation of outside-in signaling in platelets by integrin-associated protein kinase C beta. J Biol Chem 280: 644–653.
- 29. Prevost N, Mitsios JV, Kato H, Burke JE, Dennis EA, et al. (2009) Group IVA cytosolic phospholipase A2 (cPLA2alpha) and integrin alphaIIbbeta3 reinforce each other's functions during alphaIIbbeta3 signaling in platelets. Blood 113: 447–457.
- 30. Murugappa S, Kunapuli SP (2006) The role of ADP receptors in platelet function. Front Biosci 11: 1977–1986.
- 31. Nieswandt B, Schulte V, Zywietz A, Gratacap MP, Offermanns S (2002) Costimulation of Gi- and G12/G13-mediated signaling pathways induces integrin alpha IIbbeta 3 activation in platelets. J Biol Chem 277: 39493–39498.
- 32. Obergfell A, Eto K, Mocsai A, Buensuceso C, Moores SL, et al. (2002) Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton. J Cell Biol 157: 265–275.
- 33. Sada K, Takano T, Yanagi S, Yamamura H (2001) Structure and function of Syk protein-tyrosine kinase. J Biochem 130: 177–186.
- 34. Schlaepfer DD, Hauck CR, Sieg DJ (1999) Signaling through focal adhesion kinase. Prog Biophys Mol Biol 71: 435–478.
- 35. Takasaki J, Saito T, Taniguchi M, Kawasaki T, Moritani Y, et al. (2004) A novel Galphaq/11-selective inhibitor. J Biol Chem 279: 47438–47445.
- 36. Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, et al. (2007) A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 46: 488–496.
- 37. Lipinski CA, Loftus JCTargeting Pyk2 for therapeutic intervention. Expert Opin Ther Targets 14: 95–108.
- 38. Malmsten C, Kindahl H, Samuelsson B, Levy-Toledano S, Tobelem G, et al. (1977) Thromboxane synthesis and the platelet release reaction in Bernard-Soulier syndrome, thrombasthenia Glanzmann and Hermansky-Pudlak syndrome. Br J Haematol 35: 511–520.
- 39. Stefanini L, Roden RC, Bergmeier W (2009) CalDAG-GEFI is at the nexus of calcium-dependent platelet activation. Blood 114: 2506–2514.
- 40. Gong H, Shen B, Flevaris P, Chow C, Lam SC, et al. G protein subunit Galpha13 binds to integrin alphaIIbbeta3 and mediates integrin “outside-in” signaling. Science 327: 340–343.
- 41. Murugappan S, Shankar H, Bhamidipati S, Dorsam RT, Jin J, et al. (2005) Molecular mechanism and functional implications of thrombin-mediated tyrosine phosphorylation of PKCdelta in platelets. Blood 106: 550–557.
- 42. Jones ML, Shawe-Taylor AJ, Williams CM, Poole AW (2009) Characterization of a novel focal adhesion kinase inhibitor in human platelets. Biochem Biophys Res Commun 389: 198–203.
- 43. Garcia A, Shankar H, Murugappan S, Kim S, Kunapuli SP (2007) Regulation and functional consequences of ADP receptor-mediated ERK2 activation in platelets. Biochem J 404: 299–308.
- 44. Tiedt R, Schomber T, Hao-Shen H, Skoda RC (2007) Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood 109: 1503–1506.
- 45. Soriano P, Montgomery C, Geske R, Bradley A (1991) Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64: 693–702.
- 46. Jin J, Kunapuli SP (1998) Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U S A 95: 8070–8074.
- 47. Bhavaraju K, Kim S, Daniel JL, Kunapuli SP (2008) Evaluation of [3-(1-methyl-1H-indol-3-yl-methylene)-2-oxo-2, 3-dihydro-1H-indole-5-sulfonamide] (OXSI-2), as a Syk-selective inhibitor in platelets. Eur J Pharmacol 580: 285–290.